Login to Your Account



Beta Cell Regeneration Lands Evotec $345M Partnership

By Jennifer Boggs


Thursday, December 16, 2010
Though still a fairly new entrant to the metabolic disease space, courtesy of its July acquisition of DeveloGen AG, Evotec AG managed to ink an early stage partnership for a biologic beta cell regeneration program with AstraZeneca plc subsidiary MedImmune for up to €259 million (US$345.2 million).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription